Abstract
The development of effective acid-suppression therapy (particularly PPIs) has revolutionized the treatment of acid-related diseases. Despite the overall effectiveness of these agents, they have some shortcomings, including a delayed onset of action, incomplete acid suppression in the majority of patients, and the need for ingestion before a meal to achieve maximal efficacy. Attempts to overcome these issues have included the development of isomeric PPIs (such as esomeprazole), alterations in drug delivery (such as delayed-release dexlansoprazole), and combined therapy with nonenterically coated PPIs and antacids (such as 'naked' omeprazole combined with sodium biocarbonate). Other acid-suppression agents in development or in late-phase trials include potassium-competitive acid blockers, new histamine receptor 2 antagonists, and gastrin antagonists. Although these agents could potentially achieve complete gastric acid suppression, risks may be associated with this level of suppression, including enteric infections and malabsorption of nutrients such as vitamin B12, iron and calcium. This Review provides an update on the status of acid-suppression therapy and discusses directions for future research.
Key Points
-
Acid-suppression therapy can be improved to provide accelerated onset and prolonged duration of action, and avoid the need for timing of doses according to food intake
-
Isomeric PPIs, such as esomeprazole, have advantages over racemic mixtures for most (perhaps all) currently available agents
-
Delayed-release technologies, such as delayed-release dexlansoprazole, may improve the efficacy of PPI therapy
-
New agents with long half-lives, such as ilaprazole, tenatoprazole, potassium-competitive acid blockers, novel histamine receptor 2 antagonists, and gastrin antagonists, are under development and might have improved efficacy
-
Combining another agent, such as sodium bicarbonate, a histamine receptor 2 antagonist, cholecystokinin-receptor or gastrin-receptor antagonist, with a PPI may increase the efficacy of treatment
-
PPI therapy is generally safe; however, metabolic and infectious concerns and drug–drug interaction issues will need to be addressed as powerful agents with long durations of action are developed
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bell, N. J. & Hunt, R. H. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33, 118–124 (1992).
Shin, J. M. & Sachs, G. Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 10, 528–534 (2008).
Nebel, O. T., Fornes, M. F. & Castell, D. O. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am. J. Dig. Dis. 21, 953–956 (1976).
DeVault, K. R. & Castell, D. O. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch. Intern. Med. 155, 2165–2173 (1995).
Bell, N. J., Burget, D., Howden, C. W., Wilkinson, J. & Hunt, R. H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 (Suppl. 1), 59–67 (1992).
Miner, P., Katz, P. O., Chen, Y. & Sostek, M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. 98, 2616–2620 (2003).
Johnson, D. A. et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesopahgeal reflux disease. Aliment. Pharmacol. Ther. 22, 129–134 (2005).
Xue, S., Katz, P. O., Banerjee, P., Tutuian, R. & Castell, D. O. Bedtime H2 lockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment. Pharmacol. Ther. 15, 1351–1356 (2001).
Fackler, W. K., Ours, T. M., Vaezi, M. F. & Richter, J. E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122, 625–632 (2002).
Dean, B. B., Gano, A. D. Jr, Knight, K., Ofman, J. J. & Fass, R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656–664 (2004).
Hatlebakk, J. G., Katz, P. O., Camacho-Lobato, L. & Castell, D. O. Proton pump inhibitors: better acid control when taken before a meal than without a meal. Aliment. Pharmacol. Ther. 14, 1267–1272 (2000).
Hatlebakk, J. G., Katz, P. O., Kuo, B. & Castell, D. O. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther. 12, 1235–1240 (1998).
Gunaratnam, N. T., Jessup, T. P., Inadomi, J. & Lascewski, D. P. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 23, 1473–1477 (2006).
Yuan, Y. et al. The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inbitors (PPIs) in GERD trials: a meta-analysis [abstract]. Gastroenterology 134 (Suppl. 1), S174 (2008).
Hellström, P. M. & Vitols, S. The choice of proton pump inhibitor: does it matter? Basic Clin. Pharmacol. Toxicol. 94, 106–111 (2004).
Pantoflickova, D., Dorta, G., Ravic, M., Jornod, P. & Blum, A. L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 17, 1507–1514 (2003).
Erah, P. O., Goddard, A. F., Barrett, D. A., Shaw, P. N. & Spiller, R. C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39, 5–12 (1997).
Gustavson, L. E. et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39, 2078–2083 (1995).
Debets-Ossenkopp, Y. J., Namavar, F. & MacLaren, D. M. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 14, 353–355 (1995).
Figura, N., Crabtree, J. E. & Dattilo, M. In vitro activity of lansoprazole against Helicobacter pylori. J. Antimicrob. Chemother. 39, 585–590 (1997).
Gatta, L. et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J. Antimicrob. Chemother. 51, 439–442 (2003).
Laine, L. et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. 95, 3393–3398 (2000).
Gisbert, J., Domínguez-Munoz, A., Domínguez-Martin, A., Gisbert, J. L. & Marcos, S. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am. J. Gastroenterol. 100, 1935–1940 (2005).
Rostom, A. et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews, Issue 4. Art. No. CD002296. doi: 10.1002/14651858.CD002296 (2002).
Yeomans, N. D. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N. Engl. J. Med. 338, 719–726 (1998).
Yeomans, N. et al. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continuous NSAID users [Abstract]. Gastroenterology 126, A604 (2004).
Miner, P. B. et al. Pharmacokinetics of naproxen and esomeprazole in PN400, a single-tablet, multilayer formulation of enteric coated naproxen coupled with immediate-release esomeprazole [abstract]. Gastroenterology 136, T1972 (2009).
Niazi, M., Naucler, E. & Naesdal, J. A single capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg compared with the monotherapies given separately: a single-dose bioequivalence study in healthy subjects [abstract]. Gastroenterology 136, W1021 (2009).
Andriulli, A. et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicenter, randomized study. Am. J. Gastroenterol. 103, 3011–3018 (2008).
Hunt, R. H. Importance of pH control in the management of GERD. Arch. Intern. Med. 159, 649–657 (1999).
Richter, J. E. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol. 96, 656–665 (2001).
Scott, L. J., Dunn, C. J., Mallarkey, G. & Sharpe, M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 62, 1503–1538 (2002).
Castell, D. O. et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol. 97, 575–583 (2002).
Labenz, J. et al. A randomized comparitive study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment. Pharmacol. Ther. 21, 739–746 (2005).
Kim, K. A. et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin. Pharmacol. Ther. 72, 90–99 (2002).
Tanaka, M., Yamazaki, H., Hakusui, H., Nakamichi, N. & Sekino, H. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of pantoprazole: a preliminiary study. Chirality 9, 17–21 (1997).
Mano, M. et al. Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column. J. Pharm. Sci. 85, 903–907 (1996).
Pai, V. G. et al. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. World J. Gastroenterol. 12, 6017–6020 (2006).
Pai, V. & Pai, N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol. 13, 4100–4102 (2007).
Mansfield, P., Henry, D. & Tonkin, A. Single-enantiomer drugs: elegant science, disappointing effects. Clin. Pharmacokinet. 43, 287–290 (2004).
Wu, J., Vakily, M., Witt, G. & Mulford, D. TAK-390MR vs. lansoprazole for maintenance of drug concentration above a threshold which corresponds to higher time at pH >4 [abstract]. Am. J. Gastroenterol. 102, S124 (2007).
Sharma, P. et al. TAK-390MR, a proton pump inhibitor (PPI) with a novel duel delayed release formulation is highly effective in the healing of erosive esophagitis: data from two randomized controlled trials [abstract]. Gastroenterology 134, S1073 (2008).
Lee, R. D., Vakily, M., Wu, J. & Atkinson, S. The effect and timing of food on the pharmacokinetics and pharmacodynamics of TAK-390MR (modified release): evidence for dosing flexibility [abstract]. Am. J. Gastroenterol. 102, S145 (2007).
Periclou, A. P. et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin. Pharmacol. Ther. 68, 304–311 (2000).
Galmiche, J. P. et al. Tentaprazole: a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Ther. 19, 655–662 (2004).
Hunt, R. H. et al. Effect of intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol. 100, 1949–1956 (2005).
Thomson, A. B. et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment. Pharmacol. Ther. 23, 1179–1187 (2006).
Shin, J. M. et al. Characterization of the inhibitory activity of tenatoparzole on the gastric H+,K+-ATPase in vitro and in vivo. Biochem. Pharmacol. 71, 837–849 (2006).
Hunt, R. H. et al. Predictable, prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment. Pharmacol. Ther. 28, 187–197 (2008).
Castell, D. Review of immediate-release omeprazole for the treatment of gastric acid related disorders. Exp. Opin. Pharmacother. 6, 2501–2510 (2005).
Santarus Zegerid® (omeprazole/sodium bicarbonate) US full prescribing information [online], (2008).
Castell, D., Bagin, R., Goldlust, B., Major, J. & Hepburn, B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 21, 1467–1474 (2005).
Freston, J. W., Chiu, Y. L., Mulford, D. J. & Ballard, E. D. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment. Pharmacol. Ther. 17, 361–367 (2003).
Fandriks, L., Lönroth, H., Pettersson, A. & Vakil, N. Can famotidine and omeprazole be combined on a once-daily basis? Scand. J. Gastroenterol. 42, 689–694 (2007).
Chowers, Y. et al. PPI activity is optimized by VB101, a parietal cell activator [abstract]. Gastroenterology 134, A172 (2008).
Andersson, K. & Carlsson, E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Aliment. Pharmacol. Ther. 108, 294–307 (2005).
Kahrilas, P. J. et al. A randomized, comparative trial of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin. Gastroenterol. Hepatol. 5, 1385–1391 (2007).
Dent, J. et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am. J. Gastroenterol. 103, 20–26 (2008).
MedicineNet.com famotidine/calcium carbonate/magnesium hydroxide—chewable [online]
Konturek, P. C. et al. Studies on the cytoprotective and antisecretory activity of ebrotidine: a review. Arzeimittelforschung 47, 578–589 (1997).
Castillo, J. R., Torelló, J. & Hernandez, A. Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance. Eur. J. Clin. Pharmacol. 56, 187–189 (2000).
Hirakawa, N. et al. A novel histamine 2 (H2) receptor antagonist with gastroprotective activity: II. Synthesis and pharmacological evaluation of 2-furfuryl-thio and 2-furfurylsulfinyl acetamide derivatives with heteroaromatic rings. Chem. Pharm. Bull. (Tokyo) 46, 616–622 (1998).
Hersey, S. J. & Sachs, G. Gastric acid secretion. Physiol. Rev. 75, 155–189 (1995).
Chen, D. et al. Altered control of gastric acid secretion in gastrin–cholecyctokinin double mutant mice. Gastroenterology 126, 476–487 (2004).
Beltinger, J. et al. Effects of spiroglumide, a gastrin receptor antagonist, inhibits gastrin stimulated gastric acid secretion in humans [abstract]. Gut 54 (Suppl. VII), A36 (2005).
Dunlop, J. CCK receptor antagonists. Gen. Pharmacol. 31, 519–524 (1998).
Scarpignato, C., Pelosini, I. & Di Mario, F. Acid suppression therapy: where do we go from here? Dig. Dis. 24, 11–46 (2006).
Iwase, K. et al. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 113, 782–790 (1997).
Nishi, T., Makuuchi, H. & Weinstein, W. M. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus. Tokai J. Exp. Clin. Med. 30, 117–121 (2005).
Modlin, I. M., Lye, K. D. & Kidd, M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am. J. Gastroenterol. 99, 23–32 (2004).
Kuipers, E. J. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334, 1018–1022 (1996).
Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 56, 772–781 (2007).
Watson, S. A. & Smith, A. M. Hypergastrinemia promotes adenoma progression in the APCmin−/+ mouse model of familial adenomatous polyposis. Cancer Res. 61, 625–631 (2001).
Yang, Y. X. et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133, 748–754 (2007).
Chowdhury, J. R., Berkowitz, J. M., Praissman, M. & Fara, J. W. Effect of sulfated and non-sulfated gastrin and octapeptidecholecystokinin on cat gall bladder in vitro. Experientia 32, 1173–1175 (1976).
Geevasinga, N., Coleman, P. L., Webster, A. C. & Roger, S. D. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol. 4, 597–604 (2006).
Laheij, R. J. F. et al. Risk of community-acquired pneumonia and use of gastric acid–suppressive drugs. JAMA 292, 1955–1960 (2004).
Gulmez, S. E. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch. Intern. Med. 167, 950–955 (2007).
Dial, S., Delaney, J. A., Barkun, A. N. & Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294, 2989–2995 (2005).
Neal, R. K. et al. Recent treatment with H2 antagonists, antibiotics and gastric surgery as risk factors for salmonella infection [abstract]. BMJ 308, 176 (1994).
Neal, K. R., Scott, H. M., Slack, R. C. & Logan, R. F. Omeprazole as risk factor for Campylobacter gastroenteritis: case–control study. BMJ 312, 414–415 (1996).
Cobelens, F. G., Leentvarr-Kuijpers, A., Kleijnen, J. & Coutinho, R. A. Incidence and risk factors of diarrhoea in Dutch travelers: consequences for priorities in pre-travel health advice. Trop. Med. Int. Health 3, 896–903 (1998).
Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947–2953 (2006).
Recker, R. R. Calcium absorption and achlorhydria. N. Engl. J. Med. 313, 70–73 (1985).
O'Connell, M. B. et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am. J. Med. 118, 778–781 (2005).
Marcuard, S. P., Albernaz, L. & Khazanie, P. G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120, 211–215 (1994).
Conrad, M. E. & Schade, S. G. Ascorbic acid chelates in iron absorption: a role for hydorcholoric acid and bile. Gastroenterology 55, 35–45 (1968).
Koop, H. & Bachem, M. G. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J. Clin. Gastroenterol. 14, 288–292 (1992).
US Food and Drug Administration. Update of Safety Review: Follow-up to the August 9, 2007, Communication about the Ongoing Safety Review of Omeprazole and Esomeprazole [online] (2007).
Bhatt, D. L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502–1517 (2008).
Pezalla, E., Day, D. & Pulliadath, I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors [letter]. J. Am. Coll. Cardiol, 52, 1038–1039 (2008).
Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937–944 (2009).
Juurlink, D. N. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713–718 (2009).
Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).
Shaheen, N. J. The burden of gastrointestinal and liver diseases, 2006. Am. J. Gastroenterol. 101, 2128–2138 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K. R. DeVault is a Consultant for AstraZeneca and Takeda, and he receives financial support for research and education from Addex, AstraZeneca, Janssen and Takeda.
N. J. Talley is a Consultant for Astellas, AstraZeneca, Centocor, Eisai, Elsevier, Ferring, Focus Medical, Gilead, In2MedEd, Ironwood, McNeil Consumer, MedScape, Meritage, Metabolic, Microbia, Novartis, OptumHealth, Salix, SK Life Sciences, SteigerWald, The Journal of Medicine, Theravance and Wyeth. He receives financial support from Dynogen, GlaxoSmithKline and Tioga.
Rights and permissions
About this article
Cite this article
DeVault, K., Talley, N. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 6, 524–532 (2009). https://doi.org/10.1038/nrgastro.2009.125
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.125
This article is cited by
-
Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects
Clinical Drug Investigation (2021)
-
Gastroprotective effect of palmatine against acetic acid-induced gastric ulcers in rats
Journal of Natural Medicines (2017)
-
Inhibiting the proton pump: mechanisms, benefits, harms, and questions
BMC Medicine (2016)
-
Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago chilensis (Brazilian arnica) and its components quercitrin and afzelin in rodents
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)
-
Healing mechanisms of the hydroalcoholic extract and ethyl acetate fraction of green tea (Camellia sinensis (L.) Kuntze) on chronic gastric ulcers
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)